Monte Rosa Therapeutics (GLUE) Change in Accured Expenses (2020 - 2026)

Monte Rosa Therapeutics' Change in Accured Expenses history runs 7 years deep, the most recent figure standing at -$3.7 million for Q1 2026.

• In Q1 2026, Change in Accured Expenses fell 42.44% year-over-year to -$3.7 million; the TTM figure through Mar 2026 stood at $6.7 million (up 23.46% YoY), while the FY2025 annual figure was $7.9 million, up 87.67% from the prior year.
• Change in Accured Expenses for Q1 2026 stood at -$3.7 million, down from $8.7 million in the prior quarter.
• The five-year high for Change in Accured Expenses was $8.7 million in Q4 2025, with the low at -$3.9 million in Q1 2024.
• The 5-year median for Change in Accured Expenses is $1.4 million (2022), against an average of $759529.4.
• Peak annual rise in Change in Accured Expenses reached 1590.65% in 2022, while the deepest fall reached 382.25% in 2022.
• Monte Rosa Therapeutics' Change in Accured Expenses stood at $2.1 million in 2022, then tumbled by 37.79% to $1.3 million in 2023, then soared by 186.81% to $3.7 million in 2024, then jumped by 136.27% to $8.7 million in 2025, then slumped by 142.5% to -$3.7 million in 2026.
• Business Quant data shows GLUE's Change in Accured Expenses at -$3.7 million in Q1 2026, $8.7 million in Q4 2025, and $4.2 million in Q3 2025.